Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P20936
UPID:
RASA1_HUMAN
Alternative names:
Ras p21 protein activator; p120GAP
Alternative UPACC:
P20936; B2R6W3; B4DTL2; Q68CU6; Q9UDI1
Background:
Ras GTPase-activating protein 1, also known as p120GAP or Ras p21 protein activator, plays a pivotal role in cellular signaling by acting as an inhibitory regulator of the Ras-cyclic AMP pathway. It uniquely stimulates the GTPase activity of normal but not oncogenic Ras p21, a function that may be enhanced in the presence of NCK1.
Therapeutic significance:
The protein's involvement in Capillary malformation-arteriovenous malformation 1, a disorder characterized by atypical capillary malformations and potentially severe vascular anomalies, underscores its therapeutic significance. Understanding the role of Ras GTPase-activating protein 1 could open doors to potential therapeutic strategies for this autosomal dominant disease.